COVID-19 vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems, although their responses were only about one-third as strong as those mounted by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.
Information on granulocytes helps to understand mechanisms associated with covid-19 and other infectious diseases. Such information also promotes the development of better diagnostic methods and therapies.
From Novartis to Lamborghini, Alessandro Grattoni and the Houston Methodist Research Institute have partnered with big names to leverage the International Space Station U.S. National Laboratory for space-based research and technology development with important benefits back on Earth.
NYU Tandon professors Mary Cowman and Jin Ryoun Kim recently published a paper describing a novel peptide with broad therapeutic potential to combat chronic inflammation in multiple diseases.
The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen.
A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.
College is a time of transition, but for those managing chronic medical conditions, it may also be the first time they will be wholly responsible for their own health: setting appointments, securing supplies and pharmaceuticals, and monitoring symptoms.
Three independent studies in the Journal of Pharmaceutical Analysis explore the potential uses and applications of quantitative analytical tools in the characterization and quality assessment of biological and medicinal compounds.
A recent study discusses the clinical characteristics and outcomes of patients with SARDs who were previously vaccinated against SARS-CoV-2.
Scientists have developed a ‘nanobody’ – a small fragment of a llama antibody – that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.